Over the past 12‑18 months the Placenta Powder market has accelerated through a mix of strategic alliances, product innovations, and regulatory adjustments that signal a shift toward premium, science‑backed nutraceuticals. In early 2024, biotech firm NeoDerma partnered with Korean cosmetics giant AmoreBio to co‑develop a transdermal placenta‑infused serum, leveraging proprietary micro‑encapsulation technology that promises enhanced bioavailability. The same quarter saw BioGenesis acquire U.S. startup PurePlacenta Labs for $78 million, expanding its footprint in the North American dietary‑supplement segment. In July 2024, VitaCore launched its first “Placenta‑Peptide Complex” targeting anti‑aging skin care, a product line supported by clinical data published in Journal of Cosmetic Science. Regulatory momentum grew when the European Union’s Novel Food Committee granted a conditional approval for placenta‑derived powders in functional foods, prompting manufacturers to reformulate snack‑bars and protein shakes. Meanwhile, a $45 million Series B round led PlacentaPure to scale its GMP‑certified processing facility in New Zealand, positioning the company to meet rising demand from boutique wellness brands. Collectively, these Placenta Powder industry trends underscore a convergence of partnership‑driven R&D, consolidation, and evolving consumer preference for clinically validated, clean‑label ingredients.
